LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Certara Inc

Închisă

SectorSănătate

6.67 -3.61

Rezumat

Modificarea prețului

24h

Curent

Minim

6.44

Maxim

7

Indicatori cheie

By Trading Economics

Venit

3.5M

1.5M

Vânzări

46K

105M

P/E

Medie Sector

102.429

121.746

Marjă de profit

1.458

Angajați

1,487

EBITDA

-6.5M

23M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+61.37% upside

Dividende

By Dow Jones

Următoarele câștiguri

26 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-737M

1.1B

Deschiderea anterioară

10.28

Închiderea anterioară

6.67

Sentimentul știrilor

By Acuity

50%

50%

160 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Certara Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 feb. 2026, 23:57 UTC

Acțiuni populare

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 feb. 2026, 23:35 UTC

Câștiguri
Principalele dinamici ale pieței

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 feb. 2026, 23:28 UTC

Câștiguri

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 feb. 2026, 21:47 UTC

Câștiguri

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 feb. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 feb. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 feb. 2026, 23:33 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 feb. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 feb. 2026, 22:55 UTC

Câștiguri
Acțiuni populare

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 feb. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 feb. 2026, 22:23 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 feb. 2026, 21:57 UTC

Câștiguri

XP 4Q Rev BRL4.95B >XP

12 feb. 2026, 21:52 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 feb. 2026, 21:47 UTC

Câștiguri

Morningstar 4Q Rev $641M >MORN

12 feb. 2026, 21:39 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:38 UTC

Câștiguri

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Comparație

Modificare preț

Certara Inc Așteptări

Obiectiv de preț

By TipRanks

61.37% sus

Prognoză pe 12 luni

Medie 11.57 USD  61.37%

Maxim 13 USD

Minim 9 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCertara Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

6

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

11.27 / 12.79Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

160 / 352 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat